对阿尔茨海默病的运动干预进行系统审查的证据映射和质量评估
Zhengdong Xu1, Jiaxing Tang2, Wenjuan Yi3
1Department of Physical Education, Shanghai University of Engineering Science, Shanghai, China.
Complementary therapies in medicine
|July 2, 2024
概括
运动可以改善阿尔茨海默病患者的认知功能,身体功能和日常生活. 然而,大多数系统性审查 (SRs) 的方法质量较低,需要进一步研究来证实这些好处.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 物理疗法物理治疗
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 运动干预措施在缓解AD的认知衰退和功能障碍方面表现有希望.
- 系统性审查 (SRs) 对于合成基于证据的医学至关重要.
研究的目的:
- 提供关于阿兹海默症患者的运动干预措施现有证据的概述.
- 报告与AD运动相关的健康结果.
- 系统地审查和分析有关该主题的现有SRs.
主要方法:
- 在多个数据库中进行了搜索 (PubMed,Cochrane图书馆,Scopus,科学网,Embase等). 对于SRs来说,直到2023年2月.
- 使用AMSTAR 2检查清单评估获取的SR的方法质量.
- 使用PICO框架报告发现,并使用表格和泡图形可视化证据.
主要成果:
- 26个SR满足了资格标准.
- SRs的方法质量主要是低到中度 (10严重低,13低,3中度).
- 运动对阿尔茨海默病患者的认知功能,功能独立性,身体功能和神经精神症状产生了积极的影响.
结论:
- 运动干预措施对阿尔茨海默病的认知功能,身体功能,功能独立性和神经精神病症状产生积极影响.
- 经过审查的SRs的总体低到中等的方法质量表明需要更高质量的研究.
- 需要进一步严格的研究来证明运动对阿尔茨海默病患者的益处.
更多相关视频
07:27Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
10.2K
10:19Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
Published on: August 22, 2014
14.2K
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178